The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study

The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study

A clinical need for aetiotropic coronavirus disease (COVID-19) treatments is required. The immune modulator azoximer bromide (AZB; Polyoxidonium®) is indicated in Russia for use against acute viral infections and during remission. In this study, adults hospitalized with COVID-19 (n=32) received AZB...

Full description

Bibliographic Details
Main Authors: Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, Yulia S Karpova, Anton Tikhonov, Nadezhda F Khomyakova, Tim Hardman, Jean-François Rossi
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2021-03-01
Series:Drugs in Context
Subjects:
azoximer bromide (polyoxidonium®)
covid-19
inflammation
interventional study
Online Access:https://www.drugsincontext.com/the-effect-of-azoximer-bromide-polyoxidonium-in-patients-hospitalized-with-coronavirus-disease-covid-19-an-open-label-multicentre-interventional-clinical-study

Similar Items

Similar Items